Cargando…

The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial

OBJECTIVE: Non-adherence to guidelines and preventive measures is a major challenge, particularly so to obtain long-term adherence to lifestyle changes and recommended medication. The objective was to investigate if pictorial information regarding subclinical carotid atherosclerosis provided to indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bengtsson, Anna, Norberg, Margareta, Ng, Nawi, Carlberg, Bo, Grönlund, Christer, Hultdin, Johan, Lindahl, Bernt, Lindahl, Bertil, Nordin, Steven, Nyman, Emma, Wennberg, Patrik, Wester, Per, Näslund, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387279/
https://www.ncbi.nlm.nih.gov/pubmed/34611639
http://dx.doi.org/10.1016/j.ajpc.2021.100199
_version_ 1783742430064934912
author Bengtsson, Anna
Norberg, Margareta
Ng, Nawi
Carlberg, Bo
Grönlund, Christer
Hultdin, Johan
Lindahl, Bernt
Lindahl, Bertil
Nordin, Steven
Nyman, Emma
Wennberg, Patrik
Wester, Per
Näslund, Ulf
author_facet Bengtsson, Anna
Norberg, Margareta
Ng, Nawi
Carlberg, Bo
Grönlund, Christer
Hultdin, Johan
Lindahl, Bernt
Lindahl, Bertil
Nordin, Steven
Nyman, Emma
Wennberg, Patrik
Wester, Per
Näslund, Ulf
author_sort Bengtsson, Anna
collection PubMed
description OBJECTIVE: Non-adherence to guidelines and preventive measures is a major challenge, particularly so to obtain long-term adherence to lifestyle changes and recommended medication. The objective was to investigate if pictorial information regarding subclinical carotid atherosclerosis provided to individuals and physicians gave sustained effects on cardiovascular risk beyond the previously reported effect after 1 year and up to 3 years. METHODS: A Prospective Randomized Open Blinded End-point (PROBE) trial. Within a CVD prevention program in Västerbotten County, Sweden, 3532 healthy individuals aged 40, 50 or 60 years were enrolled and 1:1 randomized to intervention (n = 1749; pictorial information with additional prevention materials to participants and physicians) or control group (n = 1783; no pictorial information to participants and physicians). Preventive measures were managed within primary care. Participants were investigated at baseline during 2013–2016 and at follow-up after 1 and 3 years. RESULTS: A beneficial effect on cardiovascular risk was observed at 3-year follow-up; Framingham Risk Score (FRS) was 13.38 for the intervention group and 14.08 for the control group (p = 0.047) and SCORE was 1.69 vs. 1.82 (p = 0.022). The effect observed at 1-year was sustained over 3 years after adjustment for sex and education and more pronounced among participants with a severe atherosclerotic picture at baseline. CONCLUSIONS: This study provides evidence of sustained beneficial effects on the adherence to prevention guidelines over 3 years of pictorial information about subclinical carotid atherosclerosis, resulting in lower cardiovascular risk regardless of sex and educational level. Direct visualization of the underlying still subclinical atherosclerotic disease, rather than just indirect information about risk factors and statistical risk of future myocardial infarction, stroke and death, is one way to tackle the problem of non-adherence to prevention of cardiovascular diseases.
format Online
Article
Text
id pubmed-8387279
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83872792021-10-04 The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial Bengtsson, Anna Norberg, Margareta Ng, Nawi Carlberg, Bo Grönlund, Christer Hultdin, Johan Lindahl, Bernt Lindahl, Bertil Nordin, Steven Nyman, Emma Wennberg, Patrik Wester, Per Näslund, Ulf Am J Prev Cardiol Original Research Contribution OBJECTIVE: Non-adherence to guidelines and preventive measures is a major challenge, particularly so to obtain long-term adherence to lifestyle changes and recommended medication. The objective was to investigate if pictorial information regarding subclinical carotid atherosclerosis provided to individuals and physicians gave sustained effects on cardiovascular risk beyond the previously reported effect after 1 year and up to 3 years. METHODS: A Prospective Randomized Open Blinded End-point (PROBE) trial. Within a CVD prevention program in Västerbotten County, Sweden, 3532 healthy individuals aged 40, 50 or 60 years were enrolled and 1:1 randomized to intervention (n = 1749; pictorial information with additional prevention materials to participants and physicians) or control group (n = 1783; no pictorial information to participants and physicians). Preventive measures were managed within primary care. Participants were investigated at baseline during 2013–2016 and at follow-up after 1 and 3 years. RESULTS: A beneficial effect on cardiovascular risk was observed at 3-year follow-up; Framingham Risk Score (FRS) was 13.38 for the intervention group and 14.08 for the control group (p = 0.047) and SCORE was 1.69 vs. 1.82 (p = 0.022). The effect observed at 1-year was sustained over 3 years after adjustment for sex and education and more pronounced among participants with a severe atherosclerotic picture at baseline. CONCLUSIONS: This study provides evidence of sustained beneficial effects on the adherence to prevention guidelines over 3 years of pictorial information about subclinical carotid atherosclerosis, resulting in lower cardiovascular risk regardless of sex and educational level. Direct visualization of the underlying still subclinical atherosclerotic disease, rather than just indirect information about risk factors and statistical risk of future myocardial infarction, stroke and death, is one way to tackle the problem of non-adherence to prevention of cardiovascular diseases. Elsevier 2021-05-21 /pmc/articles/PMC8387279/ /pubmed/34611639 http://dx.doi.org/10.1016/j.ajpc.2021.100199 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Contribution
Bengtsson, Anna
Norberg, Margareta
Ng, Nawi
Carlberg, Bo
Grönlund, Christer
Hultdin, Johan
Lindahl, Bernt
Lindahl, Bertil
Nordin, Steven
Nyman, Emma
Wennberg, Patrik
Wester, Per
Näslund, Ulf
The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial
title The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial
title_full The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial
title_fullStr The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial
title_full_unstemmed The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial
title_short The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial
title_sort beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: results from the vipviza randomized clinical trial
topic Original Research Contribution
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387279/
https://www.ncbi.nlm.nih.gov/pubmed/34611639
http://dx.doi.org/10.1016/j.ajpc.2021.100199
work_keys_str_mv AT bengtssonanna thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT norbergmargareta thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT ngnawi thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT carlbergbo thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT gronlundchrister thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT hultdinjohan thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT lindahlbernt thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT lindahlbertil thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT nordinsteven thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT nymanemma thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT wennbergpatrik thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT westerper thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT naslundulf thebeneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT bengtssonanna beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT norbergmargareta beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT ngnawi beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT carlbergbo beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT gronlundchrister beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT hultdinjohan beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT lindahlbernt beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT lindahlbertil beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT nordinsteven beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT nymanemma beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT wennbergpatrik beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT westerper beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial
AT naslundulf beneficialeffectover3yearsbypictorialinformationtopatientsandtheirphysicianaboutsubclinicalatherosclerosisandcardiovascularriskresultsfromthevipvizarandomizedclinicaltrial